Table 4. (Extended) Pleurectomy/decortication plus adjuvant therapy.
| Author, [year] (Ref) | Study design | P/D (n) | Modalities | Overall morbidity (%) | Mortality (%) | Median OS (mo) |
|---|---|---|---|---|---|---|
| Achatzy et al. [1989] (49) | Retrospective | radical P/D 46; pall. P/D 72 | Adjuvant CTX + RT | NR | 4.3 (radical); 11.1 (pall) | 9.2 |
| Ruffie et al. [1989] (50) | Retrospective | 63 | +/– Adjuvant CTX +/– RT | NR | NR | 9.8 |
| Branscheid et al. [1991] (28) | Retrospective | 82 | Adjuvant CTX | NR | 2.4 | 10.4 |
| Allen et al. [1994] (29) | Retrospective | 56 | Adjuvant CTX + RT | NR | 5.4 | 9 |
| Pass et al. [1997] (51) | Prospective | 39 | PDT/CTX | NR | NR | 14.5 |
| Rusch et al. [1999] (32) | Prospective | 59 | Adjuvant CTX +/RT | 3.3 | stage I 29.9, stage II 19, stage III 10.4, stage IV 8 | |
| Aziz et al. [2002] (34) | Retrospective | 47 | Adjuvant CTX | NR | 0 | 14 |
| Schipper et al. [2008] (36) | Retrospective | sub tot. P/D 34; radical P/D 10 | Neo/adjuvant CTX +/adjuvant RT | 5.90 (sub tot), | 2.9 (sub tot); | 8.1; 17.2 |
| 20 (radical) | 0 (radical) | |||||
| Flores et al. [2008] (37) | Retrospective | 278 | Adjuvant CTX +/RT | 6.4 (respiratory only reported) | 4 | 16 |
| Nakas et al. [2008] (52) | Retrospective age 65 years | P/D 8; VATS P/D pall. 42 | Adjuvant CTX +/RT | 37.5 (P/D); | 12.5 (P/D); | 12.4; 14 |
| 47.6 (VATS P/D)(persistent air leak only reported) | 7.1 (VATS P/D) | |||||
| Rena et al. [2012] (40) | Prospective | 37 | Neo- (adjuvant CTX) + RT | 24 | 0 | 25 (stage II 23, stage I 32) |
| Nakas et al. [2012] (53) | Prospective | 67 | Neo- (adjuvant CTX) | 43 | 3 | 13.4 |
| Friedberg et al. [2012] (54) | Retrospective | 38 | Neo- (adjuvant CTX) + intraoperative PDT | NR | 2.6 | 31.7 |
| Luckraz et al. [2010] (38) | Retrospective | 90 of which 24 had TMT | All referred | 13 (TMT) | 1.1 | 26 (TMT) |
| Lang-Lazdunski et al. [2012] (55) | Prospective | 54 | Adjuvant CTX + RT HPL | 27.7 | 0 | 23 |
Studies with around 40 or more patients. P/D, pleurectomy/decortication; CTX, chemotherapy; RT, radiotherapy; PDT, photodynamic therapy; HPL, Hyperthermic pleural lavage; TMT, trimodality treatment; OS, overall survival.